Colorectal polyps in patients with limited life expectancy - BSG View

The British Society of Gastroenterology (BSG) provides guidance for managing colorectal polyps in patients with a life expectancy of less than 10 years, focusing on balancing the risks and benefits of polypectomy versus conservative management. The core challenge is evaluating the uncertain risk of polyp progression to malignancy against the procedural risks, especially in elderly or comorbid patients.

A multidisciplinary team, including gastroenterologists, surgeons, geriatricians, and patient representatives, developed these recommendations using a modified Delphi process. The guideline emphasizes that most polyps have a slow progression to malignancy, with annual transition rates ranging from 0.2% for small polyps (1–5 mm) to 10% for larger ones (≥20 mm). Given that asymptomatic colorectal cancer typically takes 3–6 years to become symptomatic, conservative management may be appropriate for patients with limited life expectancy.

The guideline recommends using the age-adjusted Charlson Comorbidity Index (CCI) and frailty scores like the Rockwood or Electronic Frailty Index to assess life expectancy and guide decision-making. Procedural risks, such as bleeding and perforation, increase with polyp size and comorbidities. Cold snare polypectomy is preferred for small polyps due to its lower complication rates. Shared decision-making, ethical considerations, and minimizing harm are central to the approach, with follow-up generally unnecessary unless in marginal cases. The guideline promotes patient-centered care and highlights the importance of training clinicians to assess frailty and avoid overtreatment.